ORBIMED ADVISORS LLC 13D/13G Filings for ARS Pharmaceuticals, Inc. (SPRY)

ORBIMED ADVISORS LLC 13D and 13G filings for ARS Pharmaceuticals, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2022-11-30
4:23 pm
Sale		 2022-11-08 13D ARS Pharmaceuticals, Inc.
SPRY		 ORBIMED ADVISORS LLC 7,788,510
8.300%		 -1decrease
(-0.00%)		 Filing
2020-12-11
4:47 pm
Purchase		 2020-12-03 13D ARS Pharmaceuticals, Inc.
SPRY		 ORBIMED ADVISORS LLC 7,788,511
22.400%		 7,788,511increase
(New Position)		 Filing